Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
SANUWAVE Health Inc Schedule 13G/A: The Vanguard Group filed Amendment No. 1 reporting 0 shares and 0% beneficial ownership of SANUWAVE common stock following an internal realignment. The filing states this change is "in accordance with SEC Release No. 34-39538 (January 12, 1998)." The amendment is signed by Ashley Grim on 03/27/2026.
Sanuwave Health reported record results for Q4 and full year 2025, with revenue of $13.4 million in Q4, up 29.7%, and full-year revenue of $44.1 million, up 35.0% from 2024. UltraMIST systems and consumables drove nearly all sales.
Q4 2025 gross margin was 74.7%, affected by a $0.5 million PACE inventory write-off, while full-year gross margin improved to 77.1% from 75.2%. Q4 operating income was $2.0 million, and full-year operating income rose to $4.9 million.
Net income reached $7.7 million in Q4 and $11.8 million for 2025, compared with net losses in 2024. Adjusted EBITDA was $4.8 million for Q4 and $13.6 million for 2025. The company guides 2026 revenue to $51.0–55.0 million, implying 16–25% growth.
Sanuwave Health reports strong growth and significant accounting changes in its annual report for the year ended December 31, 2025. Revenue reached $44.1 million, up 35% from $32.6 million in 2024, driven almost entirely by its UltraMIST ultrasound wound care system and consumables, which contributed about 99% of revenue.
The company restated prior-year and interim financial statements after identifying errors in sales tax accounting and revenue recognition for extended warranties. Management concluded these errors were material and that earlier reports should no longer be relied upon. Sanuwave also disclosed material weaknesses in internal control over financial reporting and ineffective disclosure controls.
Despite a history of losses, Sanuwave executed a secured debt refinancing in 2025 and generated net income of $11.8 million with positive operating income for both 2024 and 2025. Management believes cash flows and existing cash will fund operations and debt service for at least twelve months, while acknowledging that failure to sustain performance or financing access could again pressure its liquidity.
Sanuwave Health, Inc. determined that several previously issued quarterly and annual financial statements can no longer be relied upon due to unrecorded state sales and use tax obligations. The company plans to restate its 2024 annual results and all affected 2024–2025 interim periods in its 2025 Form 10-K.
Based on its ongoing review, Sanuwave expects to record an aggregate increase in reported liabilities of between $4.9 million and $5.2 million as of December 31, 2025. It also expects additional expenses, including taxes, interest and penalties, of $1.6 million to $1.8 million for 2024 and $1.7 million to $1.9 million for 2025. Management is evaluating the impact on internal control over financial reporting and may identify additional material weaknesses, with conclusions to be disclosed in the 2025 Form 10-K, which it expects to file on time.
SANUWAVE Health executive receives stock option grant
SANUWAVE Health, Inc. granted Exec VP of Sales David Timothy Wern a stock option for 2,500 shares of common stock on January 30, 2026. The option has an exercise price of $26.96 per share and expires on January 30, 2036.
The filing shows the full 2,500 options are held directly after the transaction. According to the footnote, these options will vest over three years in 12 equal quarterly installments starting from the grant date, tying the award to ongoing service and performance over time.
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.
The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.
Sanuwave Health, Inc. filed an amended report to update the outcome of its advisory vote on how often shareholders will be asked to approve executive compensation. After the 2025 annual meeting, where shareholders favored a one-year cycle, the Board decided on annual say-on-pay votes.
The Board resolved on January 7, 2026 to hold these advisory votes every year until the next required vote on frequency, which will occur no later than the company’s 2031 annual meeting of stockholders. No other items from the prior report were changed.
SANUWAVE Health Chief Executive Officer Morgan C. Frank, who also serves as a director, reported receiving a new stock option award. On 12/31/2025, he was granted a stock option to buy 1,540 shares of common stock at an exercise price of $29.84 per share. The filing states that these options were fully vested at the grant date, meaning they are immediately exercisable, and they carry an expiration date of 12/31/2030. After this grant, Frank beneficially owns 1,540 derivative securities in the form of these stock options, held directly.
SANUWAVE Health, Inc. director Tyler James reported receiving a stock option grant. On December 31, 2025, he was awarded 1,540 stock options giving the right to buy common stock at an exercise price of $29.84 per share. These options are shown as fully vested at the grant date and expire on December 31, 2030. After this grant, James beneficially owned 1,540 derivative securities, all held directly.
SANUWAVE Health, Inc. reported an insider equity award for director Jeffrey Blizard. On 12/31/2025, he received a stock option to purchase 1,540 shares of common stock at an exercise price of $29.84 per share, expiring on 12/31/2030.
The option was fully vested on the grant date, meaning it was immediately exercisable. Following this award, Blizard beneficially owns 1,540 derivative securities related to the company’s common stock, held as a direct ownership position.